http://pcibiotech.no/pci-biotech-receives-positive-opinion-for-orphan-drug-designation-of-fimaporfin-for-treatment-of-cholangiocarcinoma-in-eu/

TTT er vel det de sier med biotek. Jeg var på ferie i July 2016 å kjøpte meg alt jeg kunne for mine penger. Verden har vel endret seg etter det for min del.

Hva hvis igjen en melding kommer i July 2018..

Oslo, 25 July 2016 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that it has received a positive opinion from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) for its lead product candidate, fimaporfin, for the treatment of cholangiocarcinoma (bile duct cancer). COMP’s positive opinion is subject to decision by the European Commission for Orphan Designation.

Fimaporfin (AmphinexTM) is in clinical phase I/II development for inoperable bile duct cancer, a disease without approved medicinal treatment and a high need of better local treatment alternatives.

About bile duct cancer (cholangiocarcinoma) The bile duct drains bile from the liver into the small intestine. Biliary tract sepsis, liver failure and/or malnutrition and cachexia due to locoregional effects of the disease are the most important causes of death. Currently, surgery is the only curative option for these patients; yet the majority of the tumors are inoperable at presentation. Inoperable patients are treated with stenting to keep the bile duct open and with chemotherapy. The combination of gemcitabine and cisplatin has shown promising results and has become standard treatment in some regions, but there is still a need for better treatments to increase overall survival and quality of life.